Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -139.44% is 97% above its 3-year average of -5218.68%, near the high end of its 3-year range (-42960.08%–-42.70%).
33.68% below its 12-month average of -104.31%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -42.70%.
EBITDA MARGIN
-139.44%
EBITDA MARGIN AVG TTM
-104.31%
EBITDA MARGIN AVG 3Y
-5218.68%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-33.68%
CURRENT VS 3Y AVG
+97.33%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Iovance Biotherapeutics, Inc.
Market Cap
$5.87B
EBITDA Margin
-139.44%
TTM Avg
-104.31%
3Y Avg
-5218.68%
5Y Avg
N/A
Market Cap
$5.94B
EBITDA Margin
-256.72%
TTM Avg
-936.95%
3Y Avg
-3212.66%
5Y Avg
-4222.05%
Market Cap
$5.95B
EBITDA Margin
30.20%
TTM Avg
18.88%
3Y Avg
24.58%
5Y Avg
33.74%
Market Cap
$5.76B
EBITDA Margin
11.63%
TTM Avg
0.63%
3Y Avg
-0.42%
5Y Avg
-80.39%
Market Cap
$5.71B
EBITDA Margin
-4686.36%
TTM Avg
-7375.40%
3Y Avg
-15092.23%
5Y Avg
-12098.10%
Market Cap
$5.54B
EBITDA Margin
1.58%
TTM Avg
-0.29%
3Y Avg
0.97%
5Y Avg
0.97%
Market Cap
$6.33B
EBITDA Margin
-100.49%
TTM Avg
-151.66%
3Y Avg
-322.50%
5Y Avg
-1329.03%
Market Cap
$5.34B
EBITDA Margin
51.73%
TTM Avg
11.80%
3Y Avg
-10.91%
5Y Avg
-33.87%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Iovance Biotherapeutics, Inc. (IOVA) | $5.87B | -139.44% | -104.31% | -5218.68% | N/A |
| GRAIL Inc. (GRAL)vs › | $5.94B | -256.72% | -936.95% | -3212.66% | -4222.05% |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.95B | 30.20% | 18.88% | 24.58% | 33.74% |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.76B | 11.63% | 0.63% | -0.42% | -80.39% |
| CG Oncology Inc. (CGON)vs › | $5.71B | -4686.36% | -7375.40% | -15092.23% | -12098.10% |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.54B | 1.58% | -0.29% | 0.97% | 0.97% |
| RadNet, Inc. (RDNT)vs › | $5.52B | 11.91% | 12.58% | 14.79% | 16.03% |
| Rhythm Pharmaceuticals, Inc. (RYTM)vs › | $6.33B | -100.49% | -151.66% | -322.50% | -1329.03% |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.34B | 51.73% | 11.80% | -10.91% | -33.87% |
| Doximity, Inc. (DOCS)vs › | $5.32B | 35.56% | 38.69% | 36.58% | 34.55% |
Gross Margin
97.2%
EBITDA Margin
-139.4%
Operating Margin
-153.1%
Net Margin
-89.1%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -42.70% |
| 2026-03-31 | -101.50% |
| 2025-12-31 | -80.13% |
| 2025-09-30 | -127.34% |
| 2025-06-30 | -169.86% |
| 2025-03-31 | -223.33% |
| 2024-12-31 | -101.62% |
| 2024-09-30 | -133.07% |
| 2024-06-30 | -292.71% |
| 2024-03-31 | -15079.02% |
| 2023-12-31 | -23141.49% |
| 2023-09-30 | -23131.34% |
| 2023-06-30 | -42960.08% |
